Status:
UNKNOWN
Haematological Indices in Systemic Lupus Erythematosus
Lead Sponsor:
Assiut University
Conditions:
Rheumatic Diseases
Systemic Lupus Erythematosus
Eligibility:
All Genders
18-70 years
Brief Summary
The aim of this study is to investigate the value of several hematological indices such as: * neutrophil-lymphocyte ratio. * platelet-lymphocyte ratio. * red blood cell distribution width. * mean pla...
Detailed Description
Systemic lupus erythematosus (SLE) is a clinically common autoimmune disease characterized by abnormal immune response to autologous tissue, eventually resulting in systemic disorders and diverse clin...
Eligibility Criteria
Inclusion
- 1\. SLE patients who fulfills the 2012 Systemic Lupus International Collaborating Clinics (SLICC) criteria (Petri et al., 2012).
- 2\. All patients \> 18 years old.
Exclusion
- 1\. Patients with other autoimmune disease such as: Rheumatoid arthritis (RA), Mixed connective tissue disease (MTCD), Dermatomyositis (DM) and Systemic Sclerosis (SS).
- 2\. Patients with malignant diseases.
- 3\. Patients with coronary artery disease, cerebrovascular disease, renal and liver diseases.
- 4\. Patients with evidence of any concomitant inflammatory disease. Acute infection or chronic inflammatory status.
- 5\. Patients with hematological disease or history of blood transfusion in the previous 4 months.
Key Trial Info
Start Date :
December 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2023
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT04110184
Start Date
December 1 2019
End Date
February 1 2023
Last Update
October 1 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.